Search clinical trials for: SAGE-324 Placebo

Total 56569 results

Sage Therapeutics

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor

Essential Tremor

United States
Sage Therapeutics
Biogen

Active, not recruiting

Study to Evaluate SAGE-324 in Participants With Essential Tremor

Essential Tremor

United States
Sage Therapeutics

Recruiting

A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor

Essential Tremor

United States
ADARx Pharmaceuticals, Inc.

Recruiting

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients

Hereditary Angioedema

Australia
Stragen France

Completed

First-In-Human PainCart Study for STR-324

Pain

Netherlands
University of British Columbia
Canadian Institutes of Health Research (CIHR)

Completed

GrOup-based Physical Activity for oLder Adults Trial (GOAL)

Motor Activity

Canada
Sage Therapeutics

Active, not recruiting

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease | Mild Dementia

United States, Puerto Rico
Sage Therapeutics

Completed

A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

Parkinson Disease | Cognitive Dysfunction

United States
Biogen

Completed

A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model

Healthy

United States
National Yang Ming University

Recruiting

Effects of Liposomal Encapsulation on Vitamin C Absorption and Metabolism

Nutrition, Healthy

Taiwan
Global Alliance for TB Drug Development

Terminated

A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

Tuberculosis
Ohio State University

Completed

SAGE for the Early Detection of Cognitive Impairment at Primary Care Provider Visits

Cognitive Impairment

United States
Janssen Research & Development, LLC

Completed

A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)

Infarction | Ischemia | Stroke

United States
Sage Therapeutics

Recruiting

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Huntington's Disease

United States, Australia, Canada, United Kingdom
Sage Therapeutics

Active, not recruiting

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Huntington Disease

United States
Biogen

Completed

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

Bipolar Disorder I | Major Depressive Episode | Bipolar Disorder II

United States
Biogen

Completed

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

Depression, Postpartum

United States, Spain, United Kingdom
Biogen

Completed

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

Major Depressive Disorder

United States
Zagazig University

Not yet recruiting

Novel Technique Lumber Spine Fusion: Unilateral Pedicular Screws Fixation Combined With Contralateral Interbody Cage

Treatment
Biogen

Completed

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

Depressive Disorder, Major

United States
Biogen

Terminated

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

Insomnia | Major Depressive Disorder

United States
Biogen

Terminated

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

Major Depressive Disorder

United States
Biogen

Completed

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

Postpartum Depression

United States
Asmacure Ltée

Completed

Safety, Tolerability and Clinical Activity of ASM-024 in Stable Moderate Asthma

Asthma

Canada
argenx

Completed

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Kowa Company, Ltd.

Completed

K-924 Phase III Confirmatory Study

Hypercholesterolemia

Japan
Abbott

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects

Healthy

United States
Arrowhead Pharmaceuticals

Completed

Study of ARO-RAGE in Healthy Subjects

Asthma

New Zealand
China Medical University Hospital

Completed

Astragalus Membranaceus for Brain Edema Induced by Hemorrhagic Stroke

Stroke | Hemorrhagic Transformation Due to Acute Stroke
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); BerGenBio ASA

Terminated

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Brain and Central Nervous System Tumors

United States
Radicle Science

Active, not recruiting

Radicle Clarity: A Study of Health and Wellness Products on Mental Clarity and Health Outcomes

Cognitive Function

United States
Biogen

Completed

A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

Major Depression

United States
Sirtsei Pharmaceuticals, Inc.

Completed

A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Asmacure Ltée

Completed

Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)

COPD

Canada
GTx

Completed

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

Cachexia

United States, Canada
Asmacure Ltée

Completed

Safety, Tolerability and Clinical Activity of ASM-024 in Subjects With Mild Allergic Asthma

Mild Allergic Asthma

Canada
Creabilis SA

Completed

CT 327 in the Treatment of Psoriasis Vulgaris

Psoriasis

Switzerland, United States, United Kingdom
Algiax Pharmaceuticals GmbH
FGK Clinical Research GmbH

Recruiting

AP-325 in Subjects With Peripheral Post-surgical Neuropathic Pain

Peripheral Post-surgical Neuropathic Pain

Czechia, Germany, Spain, Belgium, France
NImmune Biopharma

Completed

Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers

Normal Healthy Volunteers

Australia
Frequency Therapeutics

Completed

FX-322 in Adults With Acquired Sensorineural Hearing Loss

Hearing Loss, Sensorineural | Noise Induced Hearing Loss | Sudden Hearing Loss

United States
Sirtsei Pharmaceuticals, Inc.

Completed

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

Schizophrenia

United States
Sirtsei Pharmaceuticals, Inc.
Rho, Inc.

Recruiting

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Enanta Pharmaceuticals, Inc

Completed

A Study of EDP-323 in Healthy Subjects

RSV Infection

United States
Frequency Therapeutics

Completed

FX-322 in Adults With Age-Related Sensorineural Hearing Loss

Hearing Loss, Sensorineural | Presbycusis | Noise Induced Hearing Loss | Sudden Hearing Loss

United States
Frequency Therapeutics

Completed

FX-322 in Adults With Severe Sensorineural Hearing Loss

Hearing Loss, Sensorineural | Noise Induced Hearing Loss | Sudden Hearing Loss

United States
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

Tuberculosis

United States
Frequency Therapeutics

Completed

First in Human Safety Study of FX-322 in Adults Undergoing Cochlear Implantation

Hearing Loss

Australia
Creabilis SA

Terminated

CT 327 in the Treatment of Atopic Dermatitis

Mild to Moderate Atopic Dermatitis

Switzerland
The University of The West Indies

Unknown

Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer

Stage IV Breast Cancer | Stage IV Prostate Cancer | Stage IV Colon Cancer | Stage IV Cancer of the Cervix

Jamaica
Frequency Therapeutics

Completed

FX-322 in Adults With Stable Sensorineural Hearing Loss

Sensorineural Hearing Loss | Noise Induced Hearing Loss | Sudden Sensorineural Hearing Loss

United States

3

Subscribe